United States securities and exchange commission logo





                         August 3, 2022

       Michael Poirier
       Chief Executive Officer
       Qualigen Therapeutics, Inc.
       2042 Corte Del Nogal
       Carlsbad, California 92011

                                                        Re: Qualigen
Therapeutics, Inc.
                                                            Registration
Statement on Form S-3
                                                            Filed July 29, 2022
                                                            File No. 333-266430

       Dear Mr. Poirier:

              This is to advise you that we have not reviewed and will not
review your registration
       statement.

               Please refer to Rules 460 and 461 regarding requests for
acceleration. We remind you
       that the company and its management are responsible for the accuracy and
adequacy of their
       disclosures, notwithstanding any review, comments, action or absence of
action by the staff.

                                                        Please contact Conlon
Danberg at 202-551-4466 with any questions.




                         Sincerely,


                         Division of Corporation Finance

                         Office of Life Sciences
       cc:                                              Wendy Grasso, Esq.